NCT05926960 2026-03-09
PORTSIDE
Pfizer
Phase 2 Terminated
Clinical Trials
4 trialsNCT01909453 2026-02-27
COLUMBUS
Pfizer
Phase 3 Completed
NCT03543969 2026-02-05
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT01763164 2021-03-22
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Pfizer
Phase 3 Completed